The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Biognosys turned proteomics into a true discovery technology with unprecedented precision, depth, and scale. Our industry-leading proteome coverage and high-throughput facility enable simultaneous quantification of thousands of proteins across thousands of samples. Through our proprietary technology and advanced data analytics capabilities we generate actionable insights for R&D and clinical research.
Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.
We offer a complete suite of software solutions for any mass spectrometry proteomics application in industry or academic life sciences research.
Our kits and reagents for sample preparation, quantification and quality control empower researchers to apply cutting-edge proteomics in-house.
The new and improved service will offer unprecedented depth, precision, and throughput, quantifying up to 3,000 proteins in plasma or[...]READ MORE
Biognosys is the first global proteomics service provider that is GLP certified for preclinical studies and GCP compliant for clinical[...]READ MORE
A growing number of scientific publications have been using Biognosys' technology and tools in[...]READ MORE
The agreement with Thermo Fisher Scientific is providing life science researchers with comprehensive mass spectrometry solutions to gain deep proteomic insights at a large[...]READ MORE
SpectroMine 3 comes with many novel and enhanced features for unsurpassed performance for DDA[...]READ MORE
The Partnership Will Combine Each Company’s Capabilities in Omics Research to Provide Biopharma Customers with Immunopeptidomics Insights for Drug[...]READ MORE
Highlights include workflow innovations in Plasma Proteomics and Immunopeptidomics, and enhanced Proteomics data analysis with[...]READ MORE
Cancer Scout combines Genomics, Proteomics, and Pathology data through Artificial Intelligence into a "digital biopsy" that supports early, accurate cancer diagnosis and[...]READ MORE
The new and improved workflow will offer unprecedented depth and quantitative precision, identifying up to 3,000 plasma proteins October 5th, 2021 – SCHLIEREN, (Zurich,[...]READ MORE
The Agreement Aims to Accelerate the Continuum of Diagnostic Biomarker Discovery through to Assay Development and Clinical[...]READ MORE
15 June 2021 – SCHLIEREN (Zürich – Switzerland) The leading software solution for DIA proteomics is compatible with MS instruments from all major vendors, including[...]READ MORE